18800-39-0

Basic information

• Product Name: 1-(2-BROMOETHOXY)-3-(TRIFLUOROMETHYL)BENZENE
• Synonyms: 2-BROMO-3'-(TRIFLUOROMETHYL)PHENETOLE;3-(2-BROMOETHOXY)BENZOTRIFLUORIDE;1-(2-BROMOETHOXY)-3-(TRIFLUOROMETHYL)BENZENE;3-(2-Bromomethoxy)benzotrifluoride;2-bromoethyl 3-(trifluoromethyl)phenyl ether;2-Bromo-3'-(trifluoromethyl)phenetole,1-(2-Bromoethoxy)-3-(trifluoromethyl)benzene;beta-Bromo-3-(trifluoromethyl)phenetole,1-(2-Bromoethoxy)-3-(trifluoromethyl)benzene
• CAS NO: 18800-39-0
• Molecular Formula: C₉H₈BrF₃O
• Molecular Weight: 269.06
• Mol File: 18800-39-0.mol
• Article Data: 11

Chemical Properties

• Boiling Point: 116-118
• Flash Point: 130.4°C
• Appearance: /
• Density: 1.523g/cm³
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: 1-(2-BROMOETHOXY)-3-(TRIFLUOROMETHYL)BENZENE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(2-BROMOETHOXY)-3-(TRIFLUOROMETHYL)BENZENE(18800-39-0)
• EPA Substance Registry System: 1-(2-BROMOETHOXY)-3-(TRIFLUOROMETHYL)BENZENE(18800-39-0)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26-36/37/39
• HazardClass: IRRITANT
• Hazardous Substances Data: 18800-39-0(Hazardous Substances Data)

Usage

General Description

1-(2-bromoethoxy)-3-(trifluoromethyl)benzene, also known as Bromoethoxytrifluoromethylbenzene, is an organic compound with the molecular formula C9H8BrF3O. It is a colorless liquid with a molecular weight of 259.06 g/mol and a boiling point of 137-139°C. This chemical is commonly used as a building block in the synthesis of pharmaceuticals, agrochemicals, and other organic compounds. It has potential applications in the field of synthetic chemistry and drug discovery, and its unique structure and properties make it a valuable intermediate in the production of various chemical products. However, it is important to handle this compound with caution due to its potential for causing irritation and harm if mishandled.

Upstream product

• 98-17-9 3-Trifluoromethylphenol 
• 106-93-4 ethylene dibromide 

Downstream Products

• 29969-15-1 2-(3-(trifluoromethyl)phenoxy)ethanamine 
• 321432-39-7 2-(2-(3-(trifluoromethyl)phenoxy)ethyl)isoindoline-1,3-dione 
• 18381-84-5 N-<2-(3-Trifluormethylphenyloxy)-ethyl>-cyclopropylamin 
• 70860-12-7 1,1-Dimethyl-3-{3-[2-(3-trifluoromethyl-phenoxy)-ethoxy]-phenyl}-urea 
• 69919-53-5 N'-4-[2-(3-trifluoromethylphenoxy)ethoxy]phenyl-N,N-dimethylurea 

Relevant articles and documents

Discovery of Novel pERK1/2- or β-Arrestin-Preferring 5-HT1AReceptor-Biased Agonists: Diversified Therapeutic-like versus Side Effect Profile

Novel 1-(1-benzoylpiperidin-4-yl)methanamine derivatives with high affinity and selectivity for serotonin 5-HT1A receptors were obtained and tested in four functional assays: ERK1/2 phosphorylation, adenylyl cyclase inhibition, calcium mobilization, and β-arrestin recruitment. Compounds 44 and 56 (2-methylaminophenoxyethyl and 2-(1H-indol-4-yloxy)ethyl derivatives, respectively) were selected as biased agonists with highly differential "signaling fingerprints"that translated into distinct in vivo profiles. In vitro, 44 showed biased agonism for ERK1/2 phosphorylation and, in vivo, it preferentially exerted an antidepressant-like effect in the Porsolt forced swimming test in rats. In contrast, compound 56 exhibited a first-in-class profile: it preferentially and potently activated β-arrestin recruitment in vitro and potently elicited lower lip retraction in vivo, a component of "serotonergic syndrome". Both compounds showed promising developability properties. The presented 5-HT1A receptor-biased agonists, preferentially targeting various signaling pathways, have the potential to become drug candidates for distinct central nervous system pathologies and possessing accentuated therapeutic activity and reduced side effects.

DOPAMINE D2 RECEPTOR LIGANDS

The present invention relates to novel dopamine D2 receptor ligands. The invention further relates to functionally-biased dopamine D2 receptor ligands and the use of these compounds for treating or preventing central nervous system and systemic disorders associated with dysregulation of dopaminergic activity. The present invention relates to novel compounds that modulate dopamine D2 receptors. In particular, compounds of the present invention show functional selectivity at the dopamine D2 receptors and exhibit selectivity downstream of the D2 receptors, on the 0- arrestin pathway and/or on the cAMP pathway.

New serotonin 5-HT1A receptor agonists endowed with antinociceptive activity in vivo

We report the synthesis of new compounds 4-35 based on two different openings (A and B) of the chromane ring present in the previously identified 5-HT1A receptor (5-HT1AR) ligand 3. The synthesized compounds were assessed for binding affinity, selectivity, and functional activity at the 5-HT1AR. Selected candidates resulting from B opening were also evaluated for their potential antinociceptive effect in vivo and pharmacokinetic properties in vitro. Analogue 19 [2-(4-{[2-(2-ethoxyphenoxy) ethyl]amino}butyl)tetrahydro-1H-pyrrolo[1,2-c]imidazole-1,3(2H)-dione] has been characterized as a high-affinity and potent 5-HT1AR agonist (K i = 2.3 nM; EC50 = 19 nM). Pharmacokinetic studies indicated that compound 19 displays a good metabolic stability in human liver microsomes (t1/2 ～ 3 h and CLint = 3.5 mL/min/kg, at 5 μM), and a low level of protein binding (25%, at 5 μM). Interestingly, 19 (3 mg/kg, ip, and 30 mg/kg, po) caused significant attenuation of formalin-induced behavior in early and late phases of the mouse intradermal formalin test of pain, and this in vivo effect was reversed by the selective 5-HT1AR antagonist WAY-100635. Thus, the new 5-HT1AR agonist identified in this work, 19, exhibits oral analgesic activity, and the results herein represent a step toward identifying new therapeutics for the control of pain.